SGLT2 inhibitors (SGLT2i) consistently reduce kidney outcomes across the spectrum of KDIGO classes and UACR levels in individuals with type 2 diabetes (T2D), CKD, & heart failure #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/39792537/ - ThreadSky

edgarvlermamd.bsky.social • 41 days ago

SGLT2 inhibitors (SGLT2i) consistently reduce kidney outcomes across the spectrum of KDIGO classes and UACR levels in individuals with type 2 diabetes (T2D), CKD, & heart failure
#Nephpearls #NephSky

👉 https://pubmed.ncbi.nlm.nih.gov/39792537/

1 / 4

Comments

Posting Rules

Comments

Posting Rules

Reply